Table 1 Demographic and General Characteristic of the Patients at baseline.

From: The Effect of Iranian Propolis on Glucose Metabolism, Lipid Profile, Insulin Resistance, Renal Function and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial

Variables Propolis (n = 50) Placebo (n = 44) P-Value
Age, years 55.40 ± 9.09 54.86 ± 8.89 0.77
Gender, male/female 17/33 16/28 0.81
Body height, cm 162.66 ± 8.23 162.82 ± 8.24 0.92
Body Weight, kg 79.16 ± 13.06 77.02 ± 12.48 0.42
BMI, kg/m2 30.04 ± 5.41 29.02 ± 4.08 0.31
Duration of diabetes, years 6.36 ± 3.24 6.20 ± 3.18 0.81
Physical activity level 1.53 ± 1.26 1.63 ± 0.76 0.20
Hypertension, −/+ 32/18 26/18 0.63
Hyperlipidemia, −/+ 19/31 17/27 0.76
Smoking, −/+ 43/3 42/2 0.75
Biguanides, −/+ 0/50 2/42 0.16
Sulfonylurea, −/+ 16/34 20/24 0.19
Pioglitazone, −/+ 44/6 40/4 0.65
Alpha-glucosidase inhibitor, −/+ 48/2 42/2 0.89
Dipeptiyl peptidase-IV inhibitor, −/+ 31/19 33/11 0.18
Meglitinides Derivatives 47/3 42/2 0.757
Systolic blood pressure, mmHg 133.88 ± 14.24 129.98 ± 14.87 0.89
Diastolic blood pressure, mmHg 82.32 ± 7.883 84.27 ± 7.28 0.95
  1. Data are shown as the mean ± standard deviation or number of patients. BMI, body mass index.